Determinants of nonsuppression of HIV viral load among children receiving antiretroviral therapy in the Simiyu region: a cross-sectional study.
Adherence
Antiretroviral therapy
HIV-infected children
Viral load suppression
Journal
AIDS research and therapy
ISSN: 1742-6405
Titre abrégé: AIDS Res Ther
Pays: England
ID NLM: 101237921
Informations de publication
Date de publication:
13 04 2023
13 04 2023
Historique:
received:
23
11
2022
accepted:
03
04
2023
medline:
17
4
2023
entrez:
13
4
2023
pubmed:
14
4
2023
Statut:
epublish
Résumé
Despite substantial antiretroviral therapy (ART) coverage among individuals with human immunodeficiency virus (HIV) infection in Tanzania, viral load suppression (VLS) among HIV-positive children receiving ART remains intolerably low. This study was conducted to determine factors affecting the nonsuppression of VL in children with HIV receiving ART in the Simiyu region; thus, an effective, sustainable intervention to address VL nonsuppression can be developed in the future. We conducted a cross-sectional study including children with HIV aged 2-14 years who were currently presenting to care and treatment clinics in the Simiyu region. We collected data from the children/caregivers and care and treatment center databases. We used Stata™ to perform data analysis. We used statistics, including means, standard deviations, medians, interquartile ranges (IQRs), frequencies, and percentages, to describe the data. We performed forward stepwise logistic regression, where the significance level for removal was 0.10 and that for entry was 0.05. The median age of the patients at ART initiation was 2.0 years (IQR, 1.0-5.0 years), and the mean age at HIV VL (HVL) nonsuppression was 8.8 ± 2.99 years. Of the 253 patients, 56% were female, and the mean ART duration was 64 ± 33.07 months. In multivariable analysis, independent predictors of HVL nonsuppression were older age at ART initiation (adjusted odds ratio [AOR] = 1.21; 95% confidence interval [CI] 1.012-1.443) and poor medication adherence (AOR, 0.06; 95% CI 0.004-0.867). This study showed that older age at ART initiation and poor medication adherence play significant roles in HVL nonsuppression. HIV/AIDS programs should have intensive interventions targeting early identification, ART initiation, and adherence intensification.
Sections du résumé
BACKGROUND
Despite substantial antiretroviral therapy (ART) coverage among individuals with human immunodeficiency virus (HIV) infection in Tanzania, viral load suppression (VLS) among HIV-positive children receiving ART remains intolerably low. This study was conducted to determine factors affecting the nonsuppression of VL in children with HIV receiving ART in the Simiyu region; thus, an effective, sustainable intervention to address VL nonsuppression can be developed in the future.
METHODS
We conducted a cross-sectional study including children with HIV aged 2-14 years who were currently presenting to care and treatment clinics in the Simiyu region. We collected data from the children/caregivers and care and treatment center databases. We used Stata™ to perform data analysis. We used statistics, including means, standard deviations, medians, interquartile ranges (IQRs), frequencies, and percentages, to describe the data. We performed forward stepwise logistic regression, where the significance level for removal was 0.10 and that for entry was 0.05. The median age of the patients at ART initiation was 2.0 years (IQR, 1.0-5.0 years), and the mean age at HIV VL (HVL) nonsuppression was 8.8 ± 2.99 years. Of the 253 patients, 56% were female, and the mean ART duration was 64 ± 33.07 months. In multivariable analysis, independent predictors of HVL nonsuppression were older age at ART initiation (adjusted odds ratio [AOR] = 1.21; 95% confidence interval [CI] 1.012-1.443) and poor medication adherence (AOR, 0.06; 95% CI 0.004-0.867).
CONCLUSIONS
This study showed that older age at ART initiation and poor medication adherence play significant roles in HVL nonsuppression. HIV/AIDS programs should have intensive interventions targeting early identification, ART initiation, and adherence intensification.
Identifiants
pubmed: 37055786
doi: 10.1186/s12981-023-00515-1
pii: 10.1186/s12981-023-00515-1
pmc: PMC10099818
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
22Informations de copyright
© 2023. The Author(s).
Références
Pediatr Infect Dis J. 2019 Aug;38(8):835-839
pubmed: 31033912
AIDS. 2017 Jan 28;31(3):355-364
pubmed: 27828785
BMC Infect Dis. 2019 Dec 27;19(1):1084
pubmed: 31881859
Antivir Ther. 2008;13(1):47-55
pubmed: 18389898
AIDS. 2015 Sep 24;29(15):1987-2002
pubmed: 26266773
Pediatr Infect Dis J. 2017 Jun;36(6):595-601
pubmed: 28027287
J Acquir Immune Defic Syndr. 2019 Mar 1;80(3):308-315
pubmed: 30531299
PLoS One. 2016 May 27;11(5):e0156177
pubmed: 27232185
J Int AIDS Soc. 2018 Aug;21(8):e25168
pubmed: 30094952
J Infect Dis. 2014 Mar 1;209(5):711-20
pubmed: 23943851
PLoS One. 2019 Mar 21;14(3):e0214014
pubmed: 30897131
J Infect Dis. 2005 Jul 15;192(2):296-302
pubmed: 15962224
J Acquir Immune Defic Syndr. 2017 Nov 1;76(3):319-329
pubmed: 28708808
BMC Infect Dis. 2017 May 3;17(1):326
pubmed: 28468608
AIDS. 2015 Jul 31;29(12):1527-36
pubmed: 26244392
PLoS One. 2022 Apr 14;17(4):e0261611
pubmed: 35421084
Adv Med. 2018 Jun 19;2018:6409134
pubmed: 30018988
Pediatr Infect Dis J. 2015 Mar;34(3):e63-70
pubmed: 25742090
J Pediatric Infect Dis Soc. 2021 Mar 26;10(2):131-140
pubmed: 32463083
J Pediatric Infect Dis Soc. 2021 Apr 3;10(3):295-301
pubmed: 32678875
AIDS. 2011 Aug 24;25(13):1559-73
pubmed: 21633287
AIDS. 2014 Oct 23;28(16):2395-405
pubmed: 25389551
J Antimicrob Chemother. 2022 Feb 2;77(2):483-491
pubmed: 35107140
J Int AIDS Soc. 2012 Jul 11;15 Suppl 2:17390
pubmed: 22789645
PLoS Med. 2012;9(7):e1001273
pubmed: 22910874
J Acquir Immune Defic Syndr. 2018 Oct 1;79(2):269-276
pubmed: 30211778
AIDS. 2019 Jun 1;33(7):1155-1165
pubmed: 30741823
Clin Infect Dis. 2005 Feb 15;40(4):604-8
pubmed: 15712085
AIDS. 2017 Apr 24;31(7):905-915
pubmed: 28060017
AIDS Res Hum Retroviruses. 2018 Jan;34(1):46-55
pubmed: 28670966